Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial.

Authors:
Reeder CB; Reece DE; Kukreti V; Chen C; Trudel S and 11 more

Journal:
Leukemia

Publication Year: 2009

DOI:
10.1038/leu.2009.26

PMCID:
PMC2711213

PMID:
19225538

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Leukemia

Abbreviation: Leukemia

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Hematology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Clonal medicine targeting DNA damage response eradicates leukemia.
Toma MM; Karami A; Nieborowska-Skorska M and 6 more (2024) - Transparency Score: 3/6
Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP…
Jabbour E; Apperley J; Cortes J and 17 more (2024) - Transparency Score: 3/6
LIN28B promotes differentiation of fully transformed AML cells but is dispensable for fetal leukemi…
Li Y; Mendoza-Castrejon J; Patel RM and 4 more (2024) - Transparency Score: 4/6
Lymphoma-associated hemophagocytic lymphohistiocytosis (LA-HLH): a scoping review unveils clinical …
Knauft J; Schenk T; Ernst T and 4 more (2024) - Transparency Score: 3/6
Prognostic impact of CEBPA mutational subgroups in adult AML.
Georgi JA; Stasik S; Kramer M and 35 more (2024) - Transparency Score: 4/6
View All Papers from This Journal
Transparency Score
1/6
0.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
COI Disclosure
Evidence found in paper:

"Support: This investigator initiated trial was supported by a grant from Millennium Pharmaceuticals"

Protocol Registration
Open Access
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025